BR0308527A - Solução aquosa adequada para administração intranasal, processo para a preparação da mesma, dispositivo de liberação nasal, uso de uma solução método para indução de analgesia, usos de buprenorfina, e de uma composição farmacêutica, e, composição farmacêutica - Google Patents

Solução aquosa adequada para administração intranasal, processo para a preparação da mesma, dispositivo de liberação nasal, uso de uma solução método para indução de analgesia, usos de buprenorfina, e de uma composição farmacêutica, e, composição farmacêutica

Info

Publication number
BR0308527A
BR0308527A BR0308527-9A BR0308527A BR0308527A BR 0308527 A BR0308527 A BR 0308527A BR 0308527 A BR0308527 A BR 0308527A BR 0308527 A BR0308527 A BR 0308527A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
buprenorphine
intranasal administration
preparation
release device
Prior art date
Application number
BR0308527-9A
Other languages
English (en)
Other versions
BRPI0308527B1 (pt
Inventor
Philip John Birch
Ann Gail Hayes
Peter James Watts
Jonathan David Castile
Original Assignee
Ionix Pharmaceuticals Ltd
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206448A external-priority patent/GB0206448D0/en
Priority claimed from GB0225041A external-priority patent/GB0225041D0/en
Priority claimed from GB0225042A external-priority patent/GB0225042D0/en
Priority claimed from GB0225040A external-priority patent/GB0225040D0/en
Application filed by Ionix Pharmaceuticals Ltd, West Pharm Serv Drug Res Ltd filed Critical Ionix Pharmaceuticals Ltd
Publication of BR0308527A publication Critical patent/BR0308527A/pt
Publication of BRPI0308527B1 publication Critical patent/BRPI0308527B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

"SOLUçãO AQUOSA ADEQUADA PARA ADMINISTRAçãO INTRANASAL, PROCESSO PARA A PREPARAçãO DA MESMA, DISPOSITIVO DE LIBERAçãO NASAL, USO DE UMA SOLUçãO, MéTODO PARA INDUçãO DE ANALGESIA, USOS DE BUPRENORFINA, E DE UMA COMPOSIçãO FARMACêUTICA, E, COMPOSIçãO FARMACêUTICA". As formulações aquosas adequadas para a administração intranasal compreendem buprenorfina ou um sal ou éster desta fisiologicamente aceitáveis e (a) uma pectina tendo um grau de esterificação de menos do que 50%, (b) quitosano e um copolímero de polioxietileno-polioxipropileno (poloxâmero) ou (c) quitosano e hidroxipropilmetil celulose. Tais formulações podem induzir analgesia rápida e prolongada quando intranasalmente liberadas a um paciente. A buprenorfina ou sal ou éster de buprenorfina podem ser liberados à corrente sang³inea para produzir dentro de 30 minutos uma concentração plasmática terapêutica de buprenorfina, C~ ter~ de 0,2 ng/ml ou maior que é mantida por uma duração T~ manut~ de pelo menos 2 horas.
BRPI0308527-9A 2002-03-19 2003-03-19 Solução aquosa adequada para administração intranasal, processo para a preparação de uma solução aquosa, dispositivo de liberação nasal, e uso de uma solução aquosa BRPI0308527B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0206448A GB0206448D0 (en) 2002-03-19 2002-03-19 Analgesics
GB0225041A GB0225041D0 (en) 2002-10-28 2002-10-28 Pharmaceutical formulation
GB0225042A GB0225042D0 (en) 2002-10-28 2002-10-28 Pharmaceutical composition
GB0225040A GB0225040D0 (en) 2002-10-28 2002-10-28 Formulation
PCT/GB2003/001183 WO2003080021A2 (en) 2002-03-19 2003-03-19 Formulation comprising buprenorphine

Publications (2)

Publication Number Publication Date
BR0308527A true BR0308527A (pt) 2005-02-01
BRPI0308527B1 BRPI0308527B1 (pt) 2015-07-07

Family

ID=28457822

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308527-9A BRPI0308527B1 (pt) 2002-03-19 2003-03-19 Solução aquosa adequada para administração intranasal, processo para a preparação de uma solução aquosa, dispositivo de liberação nasal, e uso de uma solução aquosa

Country Status (19)

Country Link
US (5) US7666876B2 (pt)
EP (3) EP1499360B1 (pt)
JP (3) JP2005527535A (pt)
KR (2) KR20110005919A (pt)
CN (1) CN1642577B (pt)
AT (2) ATE422902T1 (pt)
AU (2) AU2003219282A1 (pt)
BR (1) BRPI0308527B1 (pt)
CA (2) CA2479711C (pt)
DE (2) DE60326231D1 (pt)
DK (2) DK1499360T3 (pt)
ES (2) ES2315485T3 (pt)
GB (1) GB2397016B (pt)
IL (2) IL164129A0 (pt)
MX (1) MXPA04009055A (pt)
NZ (2) NZ535973A (pt)
PT (1) PT1513493E (pt)
SI (1) SI1499360T1 (pt)
WO (2) WO2003080022A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
GB0328186D0 (en) * 2003-12-05 2004-01-07 West Pharm Serv Drug Res Ltd Intranasal compositions
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
ES2399053T3 (es) * 2004-10-11 2013-03-25 Nasaleze Patents Limited Composiciones para administración intranasal
EP1824493B1 (en) * 2004-12-06 2008-08-13 Janssen Pharmaceutica N.V. Oral suspension comprising meloxicam
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
WO2007115975A2 (de) * 2006-04-04 2007-10-18 Holger Lars Hermann Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
EP2130539A4 (en) * 2007-04-02 2010-05-19 Toyo Boseki THERAPEUTIC TABLET FOR POST-HERPETIC NEURALITY AND METHOD FOR TREATMENT OF POST-HERPETIC NEURALITY
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
ES2648196T3 (es) 2008-02-07 2017-12-29 The University Of Washington Dispositivo aerosol circunferencial
CN101297973B (zh) * 2008-05-22 2010-06-09 武汉华纳生物工程有限公司 高生物粘附温敏水凝胶及其制备方法和用途
WO2010072398A2 (en) * 2008-12-22 2010-07-01 Boehringer Ingelheim Limited Veterinary formulations
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
DE102009024542A1 (de) * 2009-06-10 2010-12-16 Arivine Pharma Ag Zusammensetzungen auf Basis von Chitosan-Oligosacchariden
AU2010281436B2 (en) 2009-07-27 2016-03-24 Tonix Pharma Limited. Methods for treatment of pain
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
WO2012077024A1 (en) * 2010-12-08 2012-06-14 Mrinmayee Kondhalkar Composition for inhibiting the growth of mammalian hair
BR112013022249B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
CN103619485B (zh) 2011-05-09 2017-08-08 英倍尔药业股份有限公司 用于鼻腔药物递送的喷嘴
SG194927A1 (en) * 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
KR101944367B1 (ko) 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
US9375400B2 (en) 2011-09-14 2016-06-28 University Of South Florida Manganese ion coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2014179228A1 (en) 2013-04-28 2014-11-06 Impel Neuropharma Inc. Medical unit dose container
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
WO2015038327A1 (en) * 2013-09-10 2015-03-19 Insys Pharma, Inc. Sublingual buprenorphine spray
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
WO2015155544A1 (en) * 2014-04-10 2015-10-15 Patrick Crowley Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
WO2015195708A1 (en) * 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
CN117837746A (zh) * 2015-07-10 2024-04-09 帝斯曼知识产权资产管理有限公司 用于预防和治疗炎性疾病的食物和/或饲料组合物
JP6753927B2 (ja) 2015-09-10 2020-09-09 インペル ニューロファーマ インコーポレイテッド 直列形経鼻送達デバイス
LT3532067T (lt) * 2016-10-28 2022-08-25 Les Laboratoires Servier Liposominė vaisto forma, skirta naudoti gydant vėžį
EP3697381B1 (en) * 2017-10-20 2023-06-07 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof
WO2019104192A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
AU2019205318B2 (en) 2018-01-05 2022-02-03 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
CN112955134A (zh) 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送
KR20210109007A (ko) 2019-01-03 2021-09-03 임펠 뉴로파마 인코포레이티드 비강 약물 전달 장치
IT201900006104A1 (it) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CA3139136A1 (en) * 2019-05-14 2020-11-19 Pharmosa Biopharm Inc. Pharmaceutical composition of a weak acid drug and methods of administration
EP3969085A4 (en) 2019-05-17 2023-06-21 Impel Pharmaceuticals Inc. DISPOSABLE NASAL DELIVERY DEVICE
US20230181500A1 (en) * 2020-05-04 2023-06-15 Amphastar Pharmaceuticals, Inc. Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery
CN115011361A (zh) * 2022-06-10 2022-09-06 浙江工业大学 一种复配物乳化剂及其制备方法与应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) * 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) * 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
BE623427A (pt) * 1961-10-10
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) * 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (pt) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69222295T2 (de) 1992-05-26 1998-04-09 The Procter & Gamble Co., Cincinnati, Ohio Pulverförmige pharmazeutische Zusammensetzung
WO1994010987A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
WO1995026715A2 (en) * 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
JP3911290B2 (ja) * 1994-05-13 2007-05-09 アラダイム コーポレーション エアゾールを含む麻酔用処方
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US6667279B1 (en) * 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US5725263A (en) * 1997-04-03 1998-03-10 Rodriguez; Ernest L. Door securing device
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
DE69924504T2 (de) 1998-08-26 2006-02-16 Teijin Ltd. Pulverförmige pernasale mittel
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
US6663883B1 (en) * 1999-08-26 2003-12-16 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2003080022A3 (en) 2004-05-13
CA2479718A1 (en) 2003-10-02
JP2005526094A (ja) 2005-09-02
BRPI0308527B1 (pt) 2015-07-07
AU2003219282A1 (en) 2003-10-08
JP4728580B2 (ja) 2011-07-20
NZ535973A (en) 2007-09-28
GB2397016B (en) 2004-10-27
ES2315485T3 (es) 2009-04-01
DE60323958D1 (de) 2008-11-20
GB2397016A (en) 2004-07-14
WO2003080022A2 (en) 2003-10-02
US20050085440A1 (en) 2005-04-21
PT1513493E (pt) 2009-05-06
CN1642577A (zh) 2005-07-20
EP1513493A2 (en) 2005-03-16
DK1499360T3 (da) 2009-02-09
JP2005527535A (ja) 2005-09-15
ATE422902T1 (de) 2009-03-15
CA2479711C (en) 2011-11-29
GB0318346D0 (en) 2003-09-10
EP1499360A2 (en) 2005-01-26
KR101030403B1 (ko) 2011-04-20
US20050142072A1 (en) 2005-06-30
ES2325364T3 (es) 2009-09-02
CN1642577B (zh) 2010-05-12
AU2003216842B2 (en) 2007-12-13
DK1513493T3 (da) 2009-05-18
US20110105551A1 (en) 2011-05-05
US20100041624A1 (en) 2010-02-18
NZ535972A (en) 2006-07-28
IL164129A0 (en) 2005-12-18
JP2010174029A (ja) 2010-08-12
WO2003080021A3 (en) 2003-12-31
AU2003216842A1 (en) 2003-10-08
IL164129A (en) 2011-04-28
WO2003080021A2 (en) 2003-10-02
US20070231269A1 (en) 2007-10-04
EP1499360B1 (en) 2008-10-08
US7666876B2 (en) 2010-02-23
EP1878446A3 (en) 2008-08-27
KR20110005919A (ko) 2011-01-19
DE60326231D1 (de) 2009-04-02
EP1513493B1 (en) 2009-02-18
EP1513493B8 (en) 2009-04-22
KR20050000371A (ko) 2005-01-03
ATE410187T1 (de) 2008-10-15
EP1878446A2 (en) 2008-01-16
MXPA04009055A (es) 2005-07-27
CA2479711A1 (en) 2003-10-02
SI1499360T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
BR0308527A (pt) Solução aquosa adequada para administração intranasal, processo para a preparação da mesma, dispositivo de liberação nasal, uso de uma solução método para indução de analgesia, usos de buprenorfina, e de uma composição farmacêutica, e, composição farmacêutica
AU2002316582B2 (en) Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
IL169480A (en) Pharmaceuticals containing fentanyl for intravenous administration
JP2005527535A5 (pt)
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
UA81629C2 (ru) Применение композиции и способ лечения инфекционных заболеваний крупного рогатого скота и свиней
HK1088547A1 (en) Once daily dosage forms of trospium trospium
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
WO2003011327A3 (en) Secretin for the treatment of asthma
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
AU2006272874B2 (en) Rapid onset and short term modafinil compositions and methods of use thereof
WO2022026622A3 (en) Treatment of viral diseases
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
JP2007112735A (ja) 鎮痛用組成物
NO20005131L (no) Nye behandlinger for nervøse forstyrrelser
TWI417090B (zh) 黃酮類化合物於治療伴有感覺運動門控缺損的精神異常疾病的用途
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: IONIX PHARMACEUTICALS LIMITED (GB) , ARCHIMEDES DE

Free format text: ALTERADO DE: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY AND CLINICAL RESEARCH CENTRE LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 47/36, A61K 31/485, A61K 9/08, A61P 25/02

Ipc: A61K 47/36 (2011.01), A61K 31/485 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)